Ascentage Pharma Group International (HKG:6855) narrowed its attributable loss in 2024 to 405.4 million yuan from 925.6 million yuan in the year-ago period, a Thursday filing with the Hong Kong bourse said.
Loss per share stood at 1.34 yuan, narrower than 3.28 yuan in 2023.
The drugmaker's revenue for the year increased by 342% to 980.7 million yuan from 222 million yuan a year prior.
The higher revenue was partly attributable to intellectual property income from Takeda Pharmaceuticals International and the strong sales growth of olverembatinib.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.